Credit Suisse’s Teladoc Health TDOC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-196,900
Closed -$18.1M 4288
2021
Q4
$18.1M Buy
196,900
+81,500
+71% +$9.74M 0.01% 1138
2021
Q3
$14.6M Sell
115,400
-8,400
-7% -$1.22M 0.01% 1274
2021
Q2
$21.2M Buy
123,800
+70,700
+133% +$11.5M 0.01% 1119
2021
Q1
$9.65M Buy
+53,100
New +$12.3M ﹤0.01% 1609
2020
Q4
Sell
-6,800
Closed -$1.49M 4440
2020
Q3
$1.49M Buy
6,800
+5,300
+353% +$1.12M ﹤0.01% 2647
2020
Q2
$286K Buy
+1,500
New +$263K ﹤0.01% 3606
2020
Q1
Sell
-20,000
Closed -$1.67M 4230
2019
Q4
$1.67M Buy
20,000
+1,000
+5% +$76.1K ﹤0.01% 2757
2019
Q3
$1.29M Buy
+19,000
New +$1.25M ﹤0.01% 2819

Other funds holding TDOC

Credit Suisse's TDOC Position: Q1 2024 in Review

Credit Suisse reduced its Teladoc Health (TDOC) stake by 28% in Q1 2024, selling an estimated $6.71M and leaving 954,929 shares worth $14.4M. The position accounts for 0.01% of the portfolio, ranked #759.

Credit Suisse first reported a position in TDOC in Q3 2015 and has held it in 34 quarters since. The position peaked at $378M in Q2 2021. 426 funds tracked by Wall St. Rank hold TDOC as of Q1 2024.

  • Credit Suisse held 954,929 shares of Teladoc Health worth $14.4M as of Q1 2024.
  • Credit Suisse sold 369,818 Teladoc Health shares in Q1 2024, an estimated $6.71M.
  • Teladoc Health made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #759 holding.
  • Credit Suisse first reported a position in Teladoc Health in Q3 2015 and has held it in 34 quarters since.
  • Credit Suisse's Teladoc Health position peaked at $378M in Q2 2021.
  • 426 funds tracked by Wall St. Rank held Teladoc Health as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.